Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 30/2026 July 26, 2026
- Biallelic Loss in DDR Genes and Its Clinical Impact July 25, 2026
- How DNA “Switches” in Prostate Cancer May Open New Treatment Paths July 25, 2026
- UPDATE: VIR-5500 Extended into mHSPC July 24, 2026
Radioligand Therapy Plus CAR‑T: A New Strategy to Reprogram the Prostate Cancer Microenvironment
/in Immunotherapy, Preclinical Research/by MaxA new preclinical study shows that radioligand therapy (RLT) can directly enhance CAR‑T cell efficacy in metastatic castration-resistant prostate cancer (mCRPC), addressing two major barriers: antigen heterogeneity and an immunosuppressive tumor microenvironment (TME). Researchers combined 177Lu‑PSMA‑617 (Pluvicto) with PSCA-targeted CAR‑T cells in sequence (RLT → cyclophosphamide → CAR‑T). Compared to either treatment alone, the combination […]
Rinzimetostat and Darolutamide: Himalayas-1 Phase 3 Clinical Trial
/in Clinical Trial, Metastatic, Phase 3/by MaxHimalayas‑1 is a newly initiated global Phase 3 registrational trial testing rinzimetostat (ORIC-944) in combination with darolutamide in men with metastatic castration‑resistant prostate cancer (mCRPC) who have previously been treated with abiraterone. The trial is designed as a pivotal study intended to support approval if the results are positive, with about 600 patients planned across […]
Sonodynamic Nanotherapy: A New Strategy to Destroy Bone Metastases
/in Immunotherapy, Preclinical Research/by MaxA recent study published in Small presents a novel way to treat bone metastases by combining nanotechnology, ultrasound, and immune activation into a single strategy. While the science behind it is complex, the concept is simple: create tiny particles that travel to bone tumors and, when activated by ultrasound, generate a highly localized anti-cancer effect. […]
Fully human antibody against TβRI halts tumor growth and metastasis in preclinical prostate cancer models
/in Immunotherapy, Preclinical Research/by MaxUmeå University reports a novel fully human monoclonal antibody that blocks oncogenic signaling through the TGF‑β receptor I (TβRI), producing striking inhibition of both tumor growth and metastatic spread in aggressive prostate cancer models, according to a study published in Signal Transduction and Targeted Therapy. The antibody is composed entirely of human proteins, reducing immunogenicity […]
UPDATE: AO-252 Demonstrates 80% Clinical Benefit Rate as Development Shifts to Expansion Phase
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxAO-252, a first-in-class TACC3 inhibitor, continues to show early clinical promise in advanced solid tumours, with recent updates highlighting both improved efficacy through optimized dosing and a new formulation designed to enhance drug exposure. Interim data from an ongoing Phase 1/2 trial demonstrated a clear dosing-dependent effect. Transitioning from once-daily (QD) to twice-daily (BID) administration […]
Phase 3 Trial: Metformin in Men Receiving ADT for Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxMetformin may help blunt some of the harmful hormonal and metabolic changes caused by androgen deprivation therapy (ADT) in men with prostate cancer, according to a correlative analysis from the PRIME phase III randomized trial. ADT is a standard treatment for locally advanced and metastatic prostate cancer, but it is also associated with metabolic syndrome, […]
Soon to Start Phase 1/2 Trial: CRISPR-Edited Tregs Enter the Clinic for Solid Tumors
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxCRG-150, a CRISPR-edited regulatory T cell therapy has entered first-in-human testing for solid tumors, marking an unusual and potentially important step in oncology. The program is aimed at metastatic breast and prostate cancers, two settings where treatment options remain limited once disease becomes advanced. What makes this approach different is the cell type being used. […]
PARP Inhibition Combined with Targeted T-Cell Activation Drives Polyclonal Antitumor Immunity in mCRPC
/in Immunotherapy, Preclinical Research/by MaxA novel therapeutic strategy combining PARP inhibition with selective T-cell receptor β chain activation is showing promising potential to overcome immune resistance in metastatic castration-resistant prostate cancer (mCRPC). This approach pairs olaparib, a well-established PARP inhibitor, with a bifunctional T-cell agonist (STAR0602) designed to selectively expand specific T-cell subsets through targeted delivery of interleukin-2. Prostate […]